Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excess liver triacylglycerol (TAG), inflammation, and liver damage. The goal of the present study was to directly quantify the biological sources of hepatic and plasma lipoprotein TAG in NAFLD. Patients (5 male and 4 female; 44 +/- 10 years of age) scheduled for a medically indicated liver biopsy were infused with and orally fed stable isotopes for 4 days to label and track serum nonesterified fatty acids (NEFAs), dietary fatty acids, and those derived from the de novo lipogenesis (DNL) pathway, present in liver tissue and lipoprotein TAG. Hepatic and lipoprotein TAG fatty acids were analyzed by gas chromatography/mass spectrometry. NAFLD patients were obese, with fasting hypertriglyceridemia and hyperinsulinemia. Of the TAG accounted for in liver, 59.0% +/- 9.9% of TAG arose from NEFAs; 26.1% +/- 6.7%, from DNL; and 14.9% +/- 7.0%, from the diet. The pattern of labeling in VLDL was similar to that in liver, and throughout the 4 days of labeling, the liver demonstrated reciprocal use of adipose and dietary fatty acids. DNL was elevated in the fasting state and demonstrated no diurnal variation. These quantitative metabolic data document that both elevated peripheral fatty acids and DNL contribute to the accumulation of hepatic and lipoprotein fat in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sarcopenic obesity seems to impair insulin signaling in hepatocytes, resulting in increased de novo hepatic lipogenesis and inhibited hepatic β-oxidation [141].”
From Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences (2020) · cites this paper as [141]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, although the major source of hepatocellular triglycerides are adipose tissue-derived NEFA, the rate of hepatic de novo lipogenesis is also much greater in MASLD, further contributing to intrahepatic lipid accumulation [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Remarkably, the major fraction of hepatocellular triglycerides in people with obesity and MASLD is not derived from non-esterified fatty acids (NEFA) provided by dietary lipids, but from circulating NEFA released from adipose tissue [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
In the citing paper
“In individuals with MASLD and obesity, hepatic TG is reported to derive approximately 59% from circulating FFAs, 26% from DNL, and 15% from dietary sources [67].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [67]
In the citing paper
“IHTG was composed mainly of FFAs from SAT lipolysis (∼60%) and, to a lesser extent, FFAs from DNL (∼25%) or diet (∼15%).”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [23]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794 · cited 1×
“Given previous observations of higher fed-state DNL (23) and the known stimulatory effect of insulin on fatty acid synthesis (24), we were surprised that fed-state lipogenesis assessed at 1500 in tTRL TAG did not differ from values obtained in the fasting Figure 1 Model of lipid flux through the liver.”
ResultSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078 · cited 2×
“Insulin resistance has been shown to be associated with dysregulation of adiposederived fatty acid flux in the fasting state (10–12), and strong evidence exists demonstrating that in NAFLD patients, insulin does not suppress adipose tissue lipolysis to the same extent that it does in healthy individuals (13).”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568
Dixon, J. B., Bhathal, P. S., & O'Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,360 · cited 6×
“Dixon, J.B., Bhathal, P.S., and O’Brien, P.E. 2001.”
Influential
Research works printed but not linked: 6
- Donnelly, 2004, Diabetes., 56, A53
- 10.2337/diabetes.53.3.521 · DOI · Paper page
- Barrows, 2004, Diabetes., 56, A1388
- Timlin, 2004, Diabetes., 56, A338
- Baar, 2005, Am. J. Physiol., 288, E187
- Hellerstein, 1993, Am. J. Physiol., 265, E814
Cited by
Items 401–500 of 1,038
Pfaffenbach, K. T., Gentile, C. L., Nivala, A. M., Wang, D., Wei, Y., & Pagliassotti, M. J. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00642.2009 · Cited by 171
“A large portion of the elevated hepatic triglyceride stores in NAFLD appears to arise from reesterification of circulating free fatty acids (12).”
BackgroundFlannery, C., Dufour, S., Rabøl, R., Shulman, G. I., & Petersen, K. F. (2012) · Diabetes · doi:10.2337/db12-0206 · Cited by 168
“Hepatic DNL was more than twofold higher in the elderly than in the young subjects (elderly, 14.5 6 1.4% vs. young, 6.9 6 0.7%; P = 0.00015) and was associated with approximately threefold higher postprandial hepatic triglyceride (TG) content (P , 0.005) and increased fasting plasma TGs (elderly, 1.19 6 0.18 mmol/L vs…”
BackgroundInfluentialMetabolic interplay between white, beige, brown adipocytes and the liver
Scheja, L., & Heeren, J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.025 · Cited by 168
“Bartelt et al showed that short-term cold exposure reduced hepatic VLDL lipidation, presumably by diminishing fatty acid and lipoprotein flux to the liver [26].”
BackgroundInfluentialMitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship
Karkucińska‐Więckowska, A., Simões, I. C. M., Kalinowski, P., Lebiedzińska, M., Zieniewicz, K., Milkiewicz, P., Górska‐Ponikowska, M., Pinton, P., Malik, A. N., Krawczyk, M. J., et al. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13622 · Cited by 199
Obesity-associated mechanisms of hepatocarcinogenesis
Karagozian, R., Derdák, Z., & Baffy, G. (2014) · Metabolism · doi:10.1016/j.metabol.2014.01.011 · Cited by 171
Ma, W., Wu, J. H., Wang, Q., Lemaitre, R. N., Mukamal, K. J., Djoussé, L., King, I. B., Song, X., Biggs, M. L., Delaney, J. A., et al. (2015) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.092601 · Cited by 165
Fei, N., Bruneau, A., Zhang, X., Wang, R., Wang, J., Rabot, S., Gérard, P., & Zhao, L. (2020) · mBio · doi:10.1128/mbio.03263-19 · Cited by 168
“For example, the excessive fat deposition in the liver could be initiated by increased fatty acid delivery from adipose tissue (57); hypertrophic and hypoxic adipocytes develop an inflammatory phenotype, secreting inflammatory cytokines into circulation, which induces hepatocyte death and modulates hepatic immune func…”
BackgroundNAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
Targher, G., Corey, K. E., & Byrne, C. D. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.101215 · Cited by 165
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids
Orešič, M., Hyötyläinen, T., Kotronen, A., Gopalacharyulu, P., Nygren, H., Arola, J., Castillo, S., Mattila, I., Hakkarainen, A., Borra, R. J. H., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-2981-2 · Cited by 167
“As there is considerable similarity between the sources of fatty acids for intrahepatocellular TGs and for TG secretion by the liver in lipoproteins [13], detailed analysis of circulating molecular lipids might enable identification of biomarkers for NAFLD that reflect its pathogenesis.”
BackgroundLipotoxicity in obesity and diabetes-related cardiac dysfunction
Zlobine, I., Gopal, K., & Ussher, J. R. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.02.011 · Cited by 168
“Furthermore, obesity-induced hyperinsulinemia increases hepatic expression of lipogenic genes, de novo lipogenesis and the secretion of VLDL [36,37].”
BackgroundInfluentialGusdon, A. M., Song, K.-X., & Qu, S. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/637027 · Cited by 168
“Hepatic lipid accumulation results from a combination of uptake from circulating free fatty acids (FFAs), de novo lipogenesis, and dietary fats [2].”
Honda, Y., Imajo, K., Kato, T., Kessoku, T., Ogawa, Y., Tomeno, W., Kato, S., Mawatari, H., Fujita, K., Yoneda, M., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0146337 · Cited by 170
“In the insulin-resistant state, serum concentrations of FFAs are elevated [42] and have an important role in liver steatosis [43].”
BackgroundRole of ChREBP in hepatic steatosis and insulin resistance
Denechaud, P.-D., Dentin, R., Girard, J., & Postic, C. (2008) · FEBS Letters · doi:10.1016/j.febslet.2007.07.084 · Cited by 163
“Although the mechanisms involved in the pathogenesis of NAFLD have not been thoroughly investigated in humans, both increased de novo fatty acid synthesis and decreased b-oxidation in the mitochondria have been implicated in the development of the pathology [3,4].”
BackgroundNonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?
Valenti, L., Bugianesi, E., Pajvani, U., & Targher, G. (2016) · Liver International · doi:10.1111/liv.13185 · Cited by 171
“The contribution of DNL to HFC, which is less than 5% in healthy subjects, increases to approximately 25–30% in NAFLD (24).”
BackgroundDoege, H., Grimm, D., Falcon, A., Tsang, B., Storm, T. A., Xu, H., Ortegon, A. M., Kazantzis, M., Kay, M. A., & Stahl, A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803510200 · Cited by 169
Lautamäki, R., Borra, R., Iozzo, P., Komu, M., Lehtimäki, T., Salmi, M., Jalkanen, S., Airaksinen, K. E. J., Knuuti, J., Parkkola, R., et al. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00604.2005 · Cited by 170
“The main part of the stored triglycerides arises from the circulating FFAs (16).”
BackgroundInfluentialNon-alcoholic fatty liver disease: A sign of systemic disease
Reccia, I., Kumar, J., Akladios, C., Virdis, F., Pai, M., Habib, N., & Spalding, D. (2017) · Metabolism · doi:10.1016/j.metabol.2017.04.011 · Cited by 169
Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants
Rives, C., Fougerat, A., Ellero‐Simatos, S., Loiseau, N., Guillou, H., Gamet‐Payrastre, L., & Wahli, W. (2020) · Biomolecules · doi:10.3390/biom10121702 · Cited by 196
“Dietary lipids are involved in NAFLD but are not the main source of liver fat in NAFLD, as only 15% of hepatic lipids in NAFLD patients trace to dietary fat [17].”
BackgroundThe metabolic syndrome: common origins of a multifactorial disorder
Bruce, K. D., & Byrne, C. D. (2009) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.078014 · Cited by 165
“Analysis of hepatic TAG content has shown that fatty acids contributing to TAG accumulation were derived from a plasma supply of FFAs (59%), de novo hepatic lipogenesis (26%) and the diet (15%).”
BackgroundIL-1 Signaling in Obesity-Induced Hepatic Lipogenesis and Steatosis
Negrin, K. A., Roth Flach, R. J., DiStefano, M. T., Matevossian, A., Friedline, R. H., Jung, D., Kim, J. K., & Czech, M. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107265 · Cited by 168
“estimated de novo lipid synthesis accounts for 30% of the hepatic TG content in NAFLD patients [32].”
Backgroundter Horst, K. W., Gilijamse, P. W., Versteeg, R. I., Ackermans, M. T., Nederveen, A. J., la Fleur, S. E., Romijn, J. A., Nieuwdorp, M., Zhang, D., Samuel, V. T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.035 · Cited by 162
“Sources for Hepatic DAG Accumulation In Obese Humans Hepatic DAG may accumulate from a variety of sources including circulating FA derived from adipose tissue lipolysis (Donnelly et al., 2005; Finck and Hall, 2015).”
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
Insulin signaling to hepatic lipid metabolism in health and disease
Leavens, K. F., & Birnbaum, M. J. (2011) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2011.562481 · Cited by 164
“However, Donnelly et al. reported that in individuals with NAFLD, de novo lipogenesis is elevated even during postabsorptive states and exhibits no diurnal variation (Donnelly et al., 2005).”
BackgroundInfluentialRuiz, R., Jideonwo, V., Ahn, M., Surendran, S., Tagliabracci, V. S., Hou, Y., Gamble, A., Kerner, J., Irimia-Dominguez, J. M., Puchowicz, M. A., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.541110 · Cited by 161
“In addition, de novo lipogenesis is elevated in the fasted state and does not increase postprandially, indicating that one of the underlying causes of hepatic steatosis in non-alcoholic fatty liver disease might be the inability of the liver to regulate this pathway appropriately (33).”
BackgroundInfluentialPerakakis, N., Stefanakis, K., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154320 · Cited by 162
“Regarding LPC accumulation, animal studies have shown that interruption of the generation of LPC from PC with inhibition of PLA2 results in normalization of PC levels, prevention of NAFLD and reversal of NASH and fibrosis [158,197].”
InfluentialShabalala, S. C., Dludla, P. V., Mabasa, L., Kappo, A. P., Basson, A. K., Pheiffer, C., & Johnson, R. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110785 · Cited by 180
Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis
Lee, J. J., Lambert, J. E., Hovhannisyan, Y., Ramos-Roman, M. A., Trombold, J. R., Wagner, D. A., & Parks, E. J. (2015) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.092262 · Cited by 164
Self-citationValenzuela, R., & Videla, L. A. (2011) · Food & Function · doi:10.1039/c1fo10133a · Cited by 167
Portincasa, P., Khalil, M., Mahdi, L., Perniola, V., Idone, V., Graziani, A., Baffy, G., & Ciaula, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115640 · Cited by 181
“If the absorption of CM remnants increases, the accumulation of lipids in the liver also increases [100,101].”
BackgroundCell Culture Models of Fatty Acid Overload: Problems and Solutions
Alsabeeh, N., Chausse, B., Kakimoto, P. A., Kowaltowski, A. J., & Shirihai, O. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.11.006 · Cited by 167
Hepatic Fatty Acid Trafficking: Multiple Forks in the Road
Mashek, D. G. (2013) · Advances in Nutrition · doi:10.3945/an.113.004648 · Cited by 160
“DNL accounts for ~5% of hepatic FA during fasting and up to 30% after a meal (27,53), although rates of DNL are highly variable among people (54).”
BackgroundHepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss
Al-Mrabeh, A., Zhyzhneuskaya, S. V., Peters, C., Barnes, A. C., Melhem, S., Jesuthasan, A., Aribisala, B., Hollingsworth, K. G., Lietz, G., Mathers, J. C., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.018 · Cited by 162
“However, in the presence of muscle insulin resistance such as that seen in type 2 diabetes, the contribution of de novo lipogenesis is much greater (Donnelly et al., 2005; Flannery et al., 2012).”
BackgroundA critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism
Fisher, F. M., Kim, M., Doridot, L., Cunniff, J. C., Parker, T. S., Levine, D. M., Hellerstein, M. K., Hudgins, L. C., Maratos-Flier, E., & Herman, M. A. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2016.11.008 · Cited by 166
“Our fi ndings will motivate additional studies to investigate whether FGF21 might be used therapeutically to diminish the risks associated with NAFLD.”
InfluentialLi, M., Xu, C., Shi, J., Ding, J., Wan, X., Chen, D., Gao, J., Li, C., Zhang, J., Lin, Y., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-313778 · Cited by 158
Liu, B., Jiang, S., Li, M., Xiong, X., Zhu, M., Li, D., Zhao, L., Qian, L., Zhai, L., Li, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07185-y · Cited by 163
Di Ciaula, A., Baj, J., Garruti, G., Celano, G., De Angelis, M., Wang, H. H., Di Palo, D. M., Bonfrate, L., Wang, D. Q.-H., & Portincasa, P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082648 · Cited by 163
“• Originates from increased influx of FFAs in the liver and combination with one molecule of glycerol • Accumulates as micro-, and macro-droplets • At the early stage of NAFLD, TG represent a type of inert form protective against the ongoing lipotoxic injury [51,54]”
BackgroundLipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD)
Syed‐Abdul, M. M. (2023) · Metabolites · doi:10.3390/metabo14010012 · Cited by 181
When is steatosis too much for transplantation?
Nocito, A., El-Badry, A. M., & Clavien, P.-A. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.07.017 · Cited by 164
Koopman, K. E., Caan, M. W. A., Nederveen, A. J., Pels, A., Ackermans, M. T., Fliers, E., la Fleur, S. E., & Serlie, M. J. (2014) · Hepatology · doi:10.1002/hep.27149 · Cited by 154
“Besides the nutrients, an increased flux of portal FFA might stimulate DNL(37) since it has been reported that the plasma FFA pool accounts for 60% of IHTG in humans with nonalcoholic fatty liver disease (NAFLD).(6) Lipolysis rates from abdominal adipose tissue were not directly measured in our study, but insulin-medi…”
BackgroundSkytte, M. J., Samkani, A., Petersen, A. D., Thomsen, M. N., Astrup, A., Chabanova, E., Frystyk, J., Holst, J. J., Thomsen, H. S., Madsbad, S., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4956-4 · Cited by 158
Emerging degrader technologies engaging lysosomal pathways
Ding, Y., Xing, D., Fei, Y., & Lu, B. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00624c · Cited by 170
Johnson, N. A., Walton, D. W., Sachinwalla, T., Thompson, C. H., Smith, K., Ruell, P. A., Stannard, S. R., & George, J. (2008) · Hepatology · doi:10.1002/hep.22220 · Cited by 164
Pathophysiology of NASH: perspectives for a targeted treatment
Marra, F., & Lotersztajn, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990344 · Cited by 163
“The different types of dietary lipid may have an impact on the development of hepatic lipotoxicity, although dietary fat contributes to approximately only 10% of the hepatic FFA pool [20].”
InfluentialAlkhouri, N., Lawitz, E., Noureddin, M., DeFronzo, R., & Shulman, G. I. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1668374 · Cited by 162
“lipolysis in the context of insulin resistance [14], more recent”
BackgroundKnebel, B., Haas, J., Hartwig, S., Jacob, S., Köllmer, C., Nitzgen, U., Muller–Wieland, D., & Kotzka, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031812 · Cited by 162
“Liver-specific overespression of human SREBP-1c influences parameters of systemic insulin sensitivity Excess intracellular hepatic lipid accumulation can affect insulin sensitivity in human studies and mouse models [2,3,21].”
BackgroundTodisco, S., Santarsiero, A., Convertini, P., Stefano, G. D., Gilio, M., Iacobazzi, V., & Infantino, V. (2022) · Biology · doi:10.3390/biology11050792 · Cited by 181
“While in healthy subjects, lipogenesis is elevated in post-prandial conditions, in NAFLD subjects, lipogenesis contributes to 26% of the liver’s triglyceride content [90], and lipogenesis is already stimulated in fasting, confirming the upregulation of enzymes of liver lipogenesis also occurs in insulin resistance con…”
BackgroundLipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity
Patterson, R. E., Kalavalapalli, S., Williams, C. M., Nautiyal, M., Mathew, J. T., Martinez, J., Reinhard, M. K., McDougall, D. J., Rocca, J. R., Yost, R. A., et al. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2015 · Cited by 161
Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1
Gosis, B. S., Wada, S., Thorsheim, C., Li, K., Jung, S., Rhoades, J. H., Yang, Y., Brandimarto, J., Li, L., Uehara, K., et al. (2022) · Science · doi:10.1126/science.abf8271 · Cited by 159
“Our data provide mechanistic insight into the regulation of SREBP-1c and de novo lipogenesis, a critical component of NAFLD in humans (59, 60).”
Background(2007) · doi:10.1139/h06-102 · Cited by 160
“The term ‘‘non-alcoholic fatty liver disease’’ describes a type of ectopic fat accumulation within the liver, characterized by increased hepatic de novo lipogenesis and associated with impairment of insulin-stimulated glucose metabolism, suppression of endogenous glucose production, and whole-body lipolysis (Donnelly…”
BackgroundAberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities
De Matteis, S., Ragusa, A., Marisi, G., De Domenico, S., Casadei Gardini, A., Bonafè, M., & Giudetti, A. M. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/7512159 · Cited by 160
Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches
Lomonaco, R., Sunny, N. E., Bril, F., & Cusi, K. (2013) · Drugs · doi:10.1007/s40265-012-0004-0 · Cited by 158
“Even in the presence of high rates of TG synthesis [5] and saturated very low-density lipoprotein (VLDL) export [66], hepatic mitochondrial tricarboxylic acid cycle (TCA) activity, which is the dominant route of fat oxidation in humans, continues unabated in NAFLD subjects [67].”
BackgroundSevastianova, K., Kotronen, A., Gastaldelli, A., Perttilä, J., Hakkarainen, A., Lundbom, J., Suojanen, L., Orho-Melander, M., Lundbom, N., Ferrannini, E., et al. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.012369 · Cited by 160
Bertola, A., Deveaux, V., Bonnafous, S., Rousseau, D., Anty, R., Wakkach, A., Dahman, M., Tordjman, J., Clément, K., McQuaid, S. E., et al. (2009) · Diabetes · doi:10.2337/db08-0400 · Cited by 150
“Moreover, insulin resistance of adipose tissue leads to an enhanced delivery of free fatty acids to the liver, contributing to the excessive fatty acids accumulation (6,8).”
BackgroundHydrogen sulfide and the liver
Mani, S., Cao, W., Wu, L., & Wang, R. (2014) · Nitric Oxide · doi:10.1016/j.niox.2014.02.006 · Cited by 158
Iron and non-alcoholic fatty liver disease
Britton, L. J., Subramaniam, V. N., & Crawford, D. H. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i36.8112 · Cited by 149
Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis
Dongiovanni, P., Romeo, S., & Valenti, L. (2015) · BioMed Research International · doi:10.1155/2015/460190 · Cited by 150
“Several lines of evidence support a model where the excess in hepatocellular triglycerides derives from increased peripheral lipolysis [25] due to adipose tissue insulin resistance [26], an increased hepatic lipogenesis due to hyperinsulinemia, and an excessive food intake (Figure 1(a)).”
BackgroundNutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance
Yki-Järvinen, H. (2015) · Nutrients · doi:10.3390/nu7115454 · Cited by 154
“Studies using stable isotopes to trace pathways of hepatic triglyceride synthesis have shown that both adipose tissue lipolysis and DNL are increased in NAFLD [17,60–62] (Figure 1).”
BackgroundImpact of Dietary Palmitic Acid on Lipid Metabolism
Murru, E., Manca, C., Carta, G., & Banni, S. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.861664 · Cited by 168
Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?
Larter, C. Z., & Farrell, G. C. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.11.030 · Cited by 169
Mechanisms of Insulin Resistance in Primary and Secondary Nonalcoholic Fatty Liver
Jelenik, T., Kaul, K., Séquaris, G., Flögel, U., Phielix, E., Kotzka, J., Knebel, B., Fahlbusch, P., Hörbelt, T., Lehr, S., et al. (2017) · Diabetes · doi:10.2337/db16-1147 · Cited by 154
“Most of the TG in the livers of patients with NAFLD derives from NEFA, whereas ;26% results from DNL (5).”
BackgroundHepatic lipid metabolism and non-alcoholic fatty liver disease in aging
Gong, Z., Tas, E., Yakar, S., & Muzumdar, R. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.12.022 · Cited by 144
Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality
Brouwers, M. C. G. J., Simons, N., Stehouwer, C. D. A., & Isaacs, A. (2020) · Diabetologia · doi:10.1007/s00125-019-05024-3 · Cited by 152
Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis
Feaver, R. E., Cole, B. K., Lawson, M. J., Hoang, S. A., Marukian, S., Blackman, B. R., Figler, R. A., Sanyal, A. J., Wamhoff, B. R., & Dash, A. (2016) · JCI Insight · doi:10.1172/jci.insight.90954 · Cited by 153
“Hepatic lipid accumulation occurs in response to uptake of circulating free fatty acids (FFAs), de novo lipogenesis in the liver, or dietary fats (2) and presents as intracellular hepatocyte lipid droplet formation.”
BackgroundRector, R. S., Uptergrove, G. M., Morris, E. M., Borengasser, S. J., Laughlin, M. H., Booth, F. W., Thyfault, J. P., & Ibdah, J. A. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00510.2010 · Cited by 151
“Recent stable isotope tracer work demonstrates that 26% of hepatic TG accumulation in NAFLD patients can be accounted for by de novo lipogenesis (9), highlighting the importance of this metabolic pathway in NAFLD.”
Glucocorticoid-Induced Fatty Liver Disease
Rahimi, L., Rajpal, A., & Ismail-Beigi, F. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s247379 · Cited by 144
Kallwitz, E. R., McLachlan, A., & Cotler, S. J. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.22 · Cited by 150
Endoplasmic Reticulum Stress in Metabolic Liver Diseases and Hepatic Fibrosis
Maiers, J., & Malhi, H. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1681032 · Cited by 151
Tang, G., Xu, Y., Zhang, C., Wang, N., Li, H., & Feng, Y. (2021) · Antioxidants · doi:10.3390/antiox10071076 · Cited by 169
Lavoie, J.-M., & Gauthier, M. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6600-y · Cited by 177
Patel, V., & Sanyal, A. J. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.07.012 · Cited by 149
E2F1 mediates sustained lipogenesis and contributes to hepatic steatosis
Denechaud, P.-D., Lopez-Mejia, I. C., Giralt, A., Lai, Q., Blanchet, E., Delacuisine, B., Nicolay, B. N., Dyson, N. J., Bonner, C., Pattou, F., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81542 · Cited by 141
“Fatty acid synthesis contributes, however poorly, to lipid content in the liver under normal physiological conditions (21), which is consistent with our observation that the effects of E2F1 on lipid synthesis in normal physiology are mild.”
BackgroundHepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity
Régnier, M., Polizzi, A., Smati, S., Lukowicz, C., Fougerat, A., Lippi, Y., Fouché, E., Lasserre, F., Naylies, C., Bétoulières, C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63579-3 · Cited by 140
Yahoo, N., Dudek, M., Knolle, P., & Heikenwälder, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.033 · Cited by 137
Lipidome as a predictive tool in progression to type 2 diabetes in Finnish men
Suvitaival, T., Bondia-Pons, I., Yetukuri, L., Pöhö, P., Nolan, J. J., Hyötyläinen, T., Kuusisto, J., & Orešič, M. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.014 · Cited by 146
“a Steno Diabetes Center Copenhagen, DK-2820 Gentofte, Denmark b Institute for Molecular Medicine Finland, FI-00014, University of Helsinki, Helsinki, Finland c VTT Technical Research Centre of Finland, FI-02044 VTT, Espoo, Finland d Faculty of Pharmacy, FI-00014, University of Helsinki, Helsinki, Finland e Turku Centr…”
BackgroundInfluentialUpdates on Dietary Models of Nonalcoholic Fatty Liver Disease: Current Studies and Insights
Stephenson, K., Kennedy, L. L., Hargrove, L. A., Demieville, J., Thomson, J., Alpini, G. D., & Francis, H. (2017) · Gene Expression · doi:10.3727/105221617x15093707969658 · Cited by 167
Zhang, H., Shao, X., Zhao, H., Li, X., Wei, J., Yang, C., & Cai, Z. (2019) · Environmental Science & Technology · doi:10.1021/acs.est.8b07281 · Cited by 154
Roumans, K. H. M., Lindeboom, L., Veeraiah, P., Remie, C. M. E., Phielix, E., Havekes, B., Bruls, Y. M. H., Brouwers, M. C. G. J., Ståhlman, M., Alssema, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15684-0 · Cited by 138
Fougerat, A., Montagner, A., Loiseau, N., Guillou, H., & Wahli, W. (2020) · Cells · doi:10.3390/cells9071638 · Cited by 156
“Increased FFAs within the livers of NAFLD patients originate primarily from adipose lipolysis (59%), followed by de novo lipogenesis (26%) and diet (15%) [108,109].”
BackgroundGenetic determinants of hepatic steatosis in man
Hooper, A. J., Adams, L. A., & Burnett, J. R. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r008896 · Cited by 142
Pleiotropic genes for metabolic syndrome and inflammation
Kraja, A. T., Chasman, D. I., North, K. E., Reiner, A. P., Yanek, L. R., Kilpeläinen, T. O., Smith, J. A., Dehghan, A., Dupuis, J., Johnson, A. D., et al. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.04.007 · Cited by 146
“[70] studied 9 non-alcoholic fatty liver disease participants (with excess liver”
BackgroundBenatti, R. O., Melo, A. M., Borges, F. O., Ignacio-Souza, L. M., Simino, L. A. P., Milanski, M., Velloso, L. A., Torsoni, M. A., & Torsoni, A. S. (2014) · British Journal of Nutrition · doi:10.1017/s0007114514000579 · Cited by 145
“Donnelly et al.(51) showed that steatosis arose from circulating fatty acids in 60 % of patients and from de novo lipogenesis in 25 % of patients.”
BackgroundNon-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
Firneisz, G. (2014) · PubMed · doi:10.3748/wjg.v20.i27.9072 · Cited by 147
Hardwick, J. P., Osei-Hyiaman, D., Wiland, H., Abdelmegeed, M. A., & Song, B.-J. (2009) · PPAR Research · doi:10.1155/2009/952734 · Cited by 148
“In patients with NAFLD, 59% of TAG fatty acid is derived from adipose lipolysis while 26% is from DNL and 15% from the dietary NEFA pool [21].”
BackgroundMiyoshi, M., Ogawa, A., Higurashi, S., & Kadooka, Y. (2013) · European Journal of Nutrition · doi:10.1007/s00394-013-0568-9 · Cited by 160
“[44] reported that approximately 70 % of the lipids in the liver of nonalcoholic fatty liver disease (NAFLD) patients were derived from the adipose tissue.”
BackgroundThe unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease
Song, M. J., & Malhi, H. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107401 · Cited by 155
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
“Donnelly et al. 23 infused 13 C-ace-tate for 5 days, showing high DNL variability (12.7%-37.0% range) but no association with IHTG, which has a long turnover rate (38 ± 16 days).”
InfluentialFitness Versus Fatness: Moving Beyond Weight Loss in Nonalcoholic Fatty Liver Disease
Johnson, N. A., & George, J. (2010) · Hepatology · doi:10.1002/hep.23711 · Cited by 146
Fatty liver, insulin resistance, and dyslipidemia
Adiels, M., Taskinen, M., & Borén, J. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0011-4 · Cited by 167
Petäjä, E., & Yki-Järvinen, H. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050633 · Cited by 144
“Lipolysis is the main source of fatty acids used for synthesis of intrahepatocellular triglycerides [65,66].”
BackgroundIntestinal Fructose and Glucose Metabolism in Health and Disease
Merino, B., Fernández-Díaz, C. M., Cózar‐Castellano, I., & Perdomo, G. (2019) · Nutrients · doi:10.3390/nu12010094 · Cited by 166
Mitochondrial dysfunction in nonalcoholic fatty liver disease and alcohol related liver disease
Prasun, P., Ginevic, I., & Oishi, K. (2021) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-20-125 · Cited by 169
“The origins of FFA in hepatocytes in NAFLD are shown in Figure 2 (36).”
BackgroundSREBP Regulation of Lipid Metabolism in Liver Disease, and Therapeutic Strategies
Li, N., Li, X., Ding, Y., Liu, X., Diggle, K., Kisseleva, T., & Brenner, D. A. (2023) · Biomedicines · doi:10.3390/biomedicines11123280 · Cited by 158
Wei, Y., Wang, D., Gentile, C. L., & Pagliassotti, M. J. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0142-1 · Cited by 143
“A large portion of the elevated hepatic triglyceride stores in NAFLD appear to arise from re-esterification of circulating free fatty acids [8].”
BackgroundGambino, R., Musso, G., & Cassader, M. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.3058 · Cited by 147
“Notably, de novo lipogenesis was constitutively elevated in the fasting state and failed to increase postprandially, contrary to healthy subjects, where it rose from 5% to 23% postprandially (59, 294).”
Oh, S., So, R., Shida, T., Matsuo, T., Kim, B., Akiyama, K., Isobe, T., Okamoto, Y., Tanaka, K., & Shoda, J. (2017) · Scientific Reports · doi:10.1038/srep43029 · Cited by 146
Wang, G., Fu, Y., Xu, W., Feng, Y.-Q., Fang, S.-R., & Zhou, X. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.163 · Cited by 152
“We will verify whether other lipid-metabolic related genes are involved in the protection function of resveratrol against NAFLD.”
BackgroundInfluentialKim, A. M., Somayaji, V. R., Dong, J. Q., Rolph, T. P., Weng, Y., Chabot, J. R., Gropp, K. E., Talukdar, S., & Calle, R. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13023 · Cited by 145
“In mice, in addition to modulation of lipogenic genes and fatty acid oxidation,(6,19) FGF21 decreases TG levels through peripheral mechanism(s) increasing uptake in the adipose tissue,(20) whereas weight loss appears to be mediated primarily through the central nervous system (CNS); however, it has been reported that…”
BackgroundMetabolic Targets in Nonalcoholic Fatty Liver Disease
Esler, W. P., & Bence, K. K. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.007 · Cited by 144
Song, M., Schuschke, D. A., Zhou, Z., Chen, T., Pierce, W. M. J., Wang, R., Johnson, W. T., & McClain, C. J. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.05.030 · Cited by 145
“However, de novo lipogenesis only accounts for a small part of hepatic free fatty acids [29], therefore, it appears that impaired mitochondrial fatty acid b-oxidation likely plays an important role in fructose induced NAFLD.”
The Role of Lipid and Lipoprotein Metabolism in Non‐Alcoholic Fatty Liver Disease
Perla, F., Prelati, M., Lavorato, M., Visicchio, D., & Anania, C. (2017) · Children · doi:10.3390/children4060046 · Cited by 127
“Hepatic beta-oxidation/ketogenesis has been suggested to occur in patients with NAFLD [38,39,42,43].”
Background
Metadata
- Authors
- Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Parks, Elizabeth J.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-05-02
- Volume
- 115
- Issue
- 5
- Pages
- 1343-1351
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1087172
- OpenAlex
- W1985592156
- Semantic Scholar
- ed7633369ab77ee37699d391fe0fa59627da0df8
- Cited by
- 3,604
- References
- 50
- Citations by year
- 2026: 158 · 2025: 199 · 2024: 230 · 2023: 268 · 2022: 254 · 2021: 264 · 2020: 229 · 2019: 221 · 2018: 222 · 2017: 184 · 2016: 200 · 2015: 185 · 2014: 163 · 2013: 147 · 2012: 127
- FWCI
- 44.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- University of Minnesota
- National Institutes of Health (RR00400)
- National Institute of Diabetes and Digestive and Kidney Diseases (R03DK058286)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (PAR-98-086)
- National Center for Research Resources (M01RR000400)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- non-alcoholic fatty liver disease, hepatic triglycerides, de novo lipogenesis, free fatty acids, VLDL, stable isotope tracers, fatty acid sources, hepatic lipid accumulation, obesity, hypertriglyceridemia, hyperinsulinemia
- MeSH terms
- Adult, Fatty Acids, Fatty Liver, Female, Humans, Lipoproteins, Liver, Male, Middle Aged, Time Factors, Triglycerides, Cholesterol, VLDL
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.